Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Multiple Dose, Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa

NCT05392751 is registered in ClinicalTrials.gov with Endogena Therapeutics, Inc as lead sponsor.

NCT NCT05392751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05392751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Multiple Dose, Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa
Lead sponsor
Endogena Therapeutics, Inc
Phase
Phase 1/2
Overall status
Terminated
Start date
June 2, 2022
Completion date
April 24, 2024
Enrollment
14 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

retinitis pigmentosa, retinitis pigmentosa syndrome